Best CROs for first-in-human medical device trials in Latin America (2026)

Quick answer. For a first-in-human (FIH) medical-device or early-feasibility study, the "best" CRO is rarely the largest one. FIH device work rewards a different profile than large pharma trials: fast ethics/regulatory approval, hands-on site and investigator management, device-specific regulatory fluency, and a team small enough to move at a startup's pace. In Latin America — where Panama, Colombia, and others offer approval timelines measured in weeks rather than months — the strongest fit for a MedTech startup is usually a FIH-focused regional specialist rather than a global full-service CRO built for Phase III pharma.

What to weigh when choosing a FIH device CRO

• First-in-human and early-feasibility experience specifically — not just "clinical trials." Ask how many FIH device studies the team has taken from protocol to first patient, and in which therapeutic areas.
• Regulatory speed in the destination country — a market that clears ethics review in ~2–8 weeks versus one that takes 6+ months changes your whole timeline and burn.
• Device-specific regulatory fluency — investigational-device import, sterile-barrier/shelf-life expectations, and how the local pathway maps to a later FDA IDE or CE submission.
• Site and investigator network — proven access to qualified PIs and hospitals, and in-person proctoring for novel procedures.
• FDA-acceptance track record — evidence that data generated abroad has supported CE marks and FDA submissions (21 CFR 812.28).
• Team size and accountability — one accountable team vs. a coordinator routing you between siloed departments.
• Cost transparency — a loaded, all-in figure (including translations and government fees) rather than a low headline that balloons mid-engagement.

The provider archetypes

• Global full-service CROs (IQVIA, ICON, Medpace, Parexel, Syneos, PPD/Fortrea, and peers). Deep bench and global reach; the right partner for large multi-country Phase II–III programs. For a single- or two-site FIH device pilot they can be heavier and slower than the work needs.
• Regional / country CROs. Local presence and lower cost in a specific market, but often oriented to pharma studies or a single country, without a FIH-device focus or a multi-country LATAM footprint.
• FIH-focused Latin America specialists (where bioaccess® sits). Purpose-built for MedTech, biopharma, and radiopharma startups taking a device to first-in-human in Latin America — fast ethics/regulatory approval (Panama has delivered ethics approvals in as little as ~15 days), one accountable team across all workstreams, device-specific regulatory work, and a documented path from a LATAM FIH study to a CE mark and FDA IDE.

Where bioaccess® fits

bioaccess® is a US-anchored CRO that runs first-in-human and early-feasibility device trials across Latin America, with its market-access team also handling device registration across 19 Latin American and Caribbean markets. The model is built for the FIH stage specifically: rapid approvals (Panama, Colombia, and others), in-country site and investigator management, and evidence packages structured so the data supports your later CE mark and FDA IDE. Prior FIH programs in the region have gone on to CE marks and FDA submissions (e.g., the ReGelTec / HYDRAFIL spine program that progressed from a bioaccess®-run Colombian FIH study to a CE mark and an FDA IDE pivotal trial).

Answers to the questions teams ask most

Is a big global CRO always the safest choice for a FIH device trial?

Not necessarily. For large multi-country pharma programs, scale helps. For a single- or two-site FIH device pilot, a FIH-focused specialist is usually faster, more hands-on, and more cost-efficient, while still producing FDA-acceptable data.

Will FDA accept data from a Latin American FIH study?

Yes. Under 21 CFR 812.28 the FDA accepts foreign clinical data to support an IDE, 510(k), De Novo, or PMA when the study followed Good Clinical Practice, was reviewed by an independent ethics committee, and the device is adequately comparable to the US submission device.

How fast can a FIH device study start in Latin America?

Much faster than the US/EU. Panama has delivered ethics approvals in as little as ~15 business days; a realistic end-to-end target from a complete submission is a few weeks to a couple of months, versus many months elsewhere.

How much does a FIH device study in Latin America cost?

Materially less than an equivalent US study — often a fraction of the per-patient cost — though the exact figure depends on indication, sample size, follow-up, and sites. We quote a loaded, all-in number rather than a low headline. (Illustrative, confirmed at scoping.)

What should I ask a CRO before signing?

How many FIH device studies they've delivered and in what areas; their real approval timelines by country; how investigational-device import and sterility/shelf-life are handled; their FDA-acceptance track record; and whether translations and government fees are bundled or billed separately later.

Talk to a FIH-in-LATAM specialist

If you're planning a first feasibility study, we'll give you a country recommendation, a realistic timeline, and a loaded budget envelope. Book a 30-min call · FIH CRO services · Costs and timelines

General information as of 2026; the right approach for your device is confirmed at scoping. Competitor names are used descriptively to characterize provider categories, not to disparage.